Allspring Global Investments Holdings LLC Lowers Position in Prestige Consumer Healthcare Inc. $PBH

Allspring Global Investments Holdings LLC cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,558,104 shares of the company’s stock after selling 55,356 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Prestige Consumer Healthcare were worth $89,871,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its stake in shares of Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after acquiring an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after acquiring an additional 1,289 shares during the period. Goldman Sachs Group Inc. boosted its stake in Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after acquiring an additional 120,965 shares in the last quarter. Jane Street Group LLC grew its holdings in Prestige Consumer Healthcare by 204.0% in the first quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after purchasing an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. grew its holdings in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $49.92 on Friday. The firm’s 50-day moving average price is $47.91 and its 200-day moving average price is $57.35. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The company has a market cap of $2.36 billion, a PE ratio of 12.77, a PEG ratio of 1.63 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $77.45.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The company had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on PBH. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Canaccord Genuity Group reduced their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).